Under-diagnosis of diabetes mellitus in patients with coronary artery disease

International Journal of Cardiology

Volumn 97, Issue 1, 2004, Pages 77-82

  Kukreja, Neville ^a,b   Wilkinson, James R ^a   MacDuff, Andrew ^a   Galloway, Colin F ^a   Fox, Kim M ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

Cholesterol; Coronary angiography; Diabetes mellitus

Indexed keywords

CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET RESTRICTION; DRUG USE; FEMALE; GENERAL CONDITION IMPROVEMENT; GLUCOSE BLOOD LEVEL; HEALTH CENTER; HEART CATHETERIZATION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HEART VENTRICULOGRAPHY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT; PRIORITY JOURNAL;

CORONARY ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 4444282958     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.08.012     Document Type: Article

References (30)

1. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:1994;81-106
2. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 351:1998;1755-1762
3. Meade T.W., Brennan P.J. Determination of who may derive most benefit from aspirin in primary prevention; subgroup results from a randomised controlled trial. BMJ. 321:2000;13-17
4. Freemantle N., Cleland J., Young P., Mason J., Harrison J. Beta-Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 318:1999;1730-1737
5. Beta-Blocker Heart Attack Study Group The beta-blocker heart attack trial. JAMA. 246:1981;2073-2074
6. First International Study of Infarct Survival Collaborative Group Randomised trial of intravenous atenolol among 16. 027 cases of suspected acute myocardial infarction: ISIS-1 Lancet. 2:1986;57-66
7. The Cardiac Insufficiency Bisoprolol Study II Group The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 353:1999;9-13
8. Sharma S.K., Kini A., Marmur J.D., Fuster V. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary interventions: benefit is extended to improvement in intermediate-term survival. Circulation. 102:2000;166-172
9. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333:1995;1301-1307
10. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389
11. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339:1998;1349-1357
12. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N. Engl. J. Med. 335:1996;1001-1009
13. Pitt B., Waters D., Brown W.V., et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N. Engl. J. Med. 341:1999;70-76
14. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828
15. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N. Engl. J. Med. 327:1992;685-691
16. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342:2000;145-153
17. The Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of HOPE study and MICRO-HOPE substudy. Lancet. 355:2000;253-259
18. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 343:1994;1115-1122
19. Eccles M., Bradshaw C. Use of secondary prophylaxis against myocardial infarction in the north of England. BMJ. 302:1991;91-92
20. Department of Health. National Service Framework for Coronary Heart Disease - modern standards and service methods. Crown Copyright; 2000.
21. World Health Organization, Department of Noncommunicable Disease Surveillance Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation: Part 1. Diagnosis and Classification of Diabetes Mellitus. 1999;WHO, Geneva, Switzerland
22. Detre K.M., Lombardero M.S., Brooks M.M., et al. The effect of previous coronary artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. N. Engl. J. Med. 342:2000;989-997
23. Stables R.H. An audit of lipid screening and management in patients undergoing diagnostic cardiac catheterisation. Eur. Heart J. 17:1996;1657-1662
24. Royal Brompton Hospital Senior House Officer Group Audit of Lipid Management. 1999;. Unpublished
25. Nisar M., Earis J.E., Pearson M.G., Calverley P.M. Acute bronchodilator trials in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 146:1992;555-559
26. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329:1993;977-986
27. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853
28. Chaturvedi N., Sjole A.K., Stephenson J.M., et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 351:1998;28-31
29. The EUCLID Study Group Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 349:1997;1787-1792
30. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329:1993;1456-1462